Evidence map›Paper›PMID 32071281›Full record

ReviewRMD open2020

Treat-to-target in PsA: methods and necessity.

Emma Dures, Sasha Shepperd, Sandeep Mukherjee, Jo Robson, Ivo Vlaev, Nicola Walsh, Laura C Coates

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in RMD open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Observational
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Emma DuresDepartment of Nursing and Midwifery, University of the West of England Bristol, Bristol, UK.
Sasha ShepperdNuffield Department of Population Health, University of Oxford, Oxford, Oxfordshire, UK.
Sandeep MukherjeeDepartment of Rheumatology, Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, UK.
Jo RobsonHealth and Applied Sciences, University of the West of England Bristol, Bristol, UK.
Ivo VlaevWarwick Business School, Coventry, UK.
Nicola WalshCentre for Health and Clinical Research, University of the West of England Bristol, Bristol, UK.
Laura C CoatesNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK laura.coates@ndorms.ox.ac.uk.ORCID 0000-0002-4756-663X
University of the West of England · GBNuffield Orthopaedic Centre · GBRoyal Bournemouth and Christchurch Hospitals NHS Foundation Trust · GBUniversity of Oxford · GBUniversity of Warwick · GB

Funding

Department of Health CS-2016-16-016
6 · The paper itself

Abstract

With increasing recognition of the high burden and impact of psoriatic arthritis (PsA) and the growing number of therapeutic options, there has been an intensifying focus on treatment strategy in recent years. In 2015, the Tight Control of Psoriatic Arthritis study confirmed the clinical benefit of using a treat-to-target approach in PsA. This randomised controlled trial found benefits in both arthritis and psoriasis disease activity as well as lower disease impact reported by patients, although participants allocated to tight control experienced a higher rate of serious adverse events. European and international recommendations support the use of a treat-to-target approach in PsA and have offered specific advice on how to do this using outcomes such as the minimal disease activity criteria. However, implementation of this approach in routine practice is low, with real-world data highlighting undertreatment as a result. Recent qualitative work with physicians in the UK has helped researchers to understand the barriers to implementation of treat-to-target in PsA. We now need to address these barriers, provide education and support to non-specialist clinicians in routine practice, and aid the translation of optimal care to the clinic.

Indexed as

Antirheumatic AgentsArthritis, PsoriaticCost of IllnessEvidence-Based MedicineHumansPatient Reported Outcome MeasuresQuality of LifeRandomized Controlled Trials as TopicRemission InductionSeverity of Illness IndexAntirheumatic Agentshealth services researchpsoriatic arthritistreatment

Identifiers

PMID32071281
PMCPMC7046962
OpenAlexW3004919658

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.